Takeda Pharmaceutical Co., Ltd: PharmaVitae Profile

Introduction
This analysis examines the historical and forecast performance for Takeda in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits
Gain insight into Takeda's strategic outlook across the next 6 years
Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
Highlights
Strategic insight into the prospects for Takeda over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered
Benchmark Takeda's performance against key rivals in the prescription pharmaceutical sector
Discover if Takeda will overcome generic competition facing its biggest selling medications
Investigate the diverse strategies being employed by Japan's oldest and largest pharmaceutical player
[Studien Infos ausblenden]

TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2003–15 6
Financial performance, 2003–15 8
Takeda: PharmaVitae forecasts at a glance 9
Strategic insight 10
SWOT analysis 15
Chapter 3 Quarterly news update 22
Latest prescription pharma product news 22
Latest corporate news 25
Future product milestones 27
Chapter 4 Company introduction 28
Key findings 28
Background 29
Key corporate developments 29
M&A history 31
Chapter 5 Company sales 33
Key findings 33
Prescription pharmaceutical sales and growth rate analysis, 2003–15 34
Product analysis 36
Therapy area analysis 42
Geographic analysis 44
Launch/core/expiry analysis 46
Molecule type analysis 51
Externalization analysis 53
Chapter 6 Company financials 55
Key findings 55
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09 56
Operating costs and profit analysis 57
Chapter 7 Key products 62
Overview 62
Chapter 8 Appendix 93
References 93
Abbreviations 93
Exchange rates 95
About Datamonitor 96
Datamonitor consulting 96
Disclaimer 98


TABLE OF TABLES
Table 1: Takeda – PharmaVitae forecasts at a glance 9
Table 2: Takeda future product milestones, 2010–12 27
Table 3: Takeda product portfolio overview ($m), 2003–09 37
Table 4: Takeda product portfolio overview ($m), 2009–15 39
Table 5: Takeda prescription pharmaceutical sales by therapy area ($m), 2009–15 43
Table 6: Takeda prescription pharmaceutical sales by geographic region ($m), 2009–15 45
Table 7: Takeda launch portfolio overview ($m), 2009–15 47
Table 8: Takeda core portfolio overview ($m), 2009–15 48
Table 9: Takeda expiry portfolio overview ($m), 2009–15 49
Table 10: Takeda prescription pharmaceutical sales by molecule type ($m), 2009–15 52
Table 11: Takeda prescription pharmaceutical sales by source ($m), 2009–15 54
Table 12: Total Takeda sales by business unit ($m), 2003–09 56
Table 13: Takeda operating revenue/cost analysis ($m), 2003–09 58
Table 14: Takeda operating cost ratio analysis (% of total revenues), 2003–09 59
Table 15: Takeda operating cost ratio analysis (% of total revenues), 2009–15 60
Table 16: Takeda operating revenue/cost analysis ($m), 2009–15 61
Table 17: Takeda Key products overview 62
Table 18: Dexilant: overview 64
Table 19: Dexilant: sales forecast ($m), 2009–15 65
Table 20: Blopress: overview 67
Table 21: Blopress comp: overview 68
Table 22: Blopress: sales forecast ($m), 2009–15 69
Table 23: Blopress comp: sales forecast ($m), 2009–15 69
Table 24: Actos: overview 72
Table 25: ACTOplus met: overview 73
Table 26: Actos: sales forecast ($m), 2009–15 74
Table 27: ACTOplus met: sales forecast ($m), 2009–15 74
Table 28: Lupron Depot: overview 77
Table 29: Lupron Depot: sales forecast ($m), 2009–15 78
Table 30: Velcade: overview 80
Table 31: Velcade: sales forecast ($m), 2009–15 81
Table 32: Alogliptin: overview 83
Table 33: Alogliptin/ACTOS combo: overview 84
Table 34: Alogliptin: sales forecast ($m), 2009–15 85
Table 35: Alogliptin/ACTOS combo: sales forecast ($m), 2009–15 85
Table 36: Enbrel: overview 88
Table 37: Enbrel: sales forecast ($m), 2009–15 89
Table 38: Amitiza: overview 91
Table 39: Amitiza: sales forecast ($m), 2009–15 92
Table 40: Exchange rates, 2010 95


TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: Takeda prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 7
Figure 3: Takeda’s financial performance ($m), 2003–15 8
Figure 4: Major expiry product sales ($m), 2009–15 10
Figure 5: Oncology investment drives long-term therapeutic strategy 12
Figure 6: Lifecycle management of gastroenterology portfolio, sales ($m), 2009–15 13
Figure 7: Lifecycle management of antidiabetic portfolio, sales ($m), 2009–15 14
Figure 8: Takeda SWOT analysis 15
Figure 9: Takeda prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 35
Figure 10: Takeda Key product sales ($m), 2003–15 36
Figure 11: Takeda key sales growth drivers and resistors ($m), 2003–09 38
Figure 12: Takeda key sales growth drivers and resistors ($m), 2009–15 40
Figure 13: Takeda prescription pharmaceutical sales by therapy area ($m), 2003–15 42
Figure 14: Takeda prescription pharmaceutical sales by geographic region ($m), 2003–15 44
Figure 15: Takeda launch/core/expiry configuration ($m), 2009–15 50
Figure 16: Takeda prescription pharmaceutical sales by molecule type ($m), 2003–15 51
Figure 17: Takeda prescription pharmaceutical sales by source ($m), 2003-15 53
Figure 18: Takeda operating revenue/cost analysis ($m), 2003–15 57
Figure 19: Dexilant sales by geography and analyst consensus ($m), 2003–15 65
Figure 20: Blopress sales by geography and analyst consensus ($m), 2003–15 70
Figure 21: Blopress comp sales by geography and analyst consensus ($m), 2003–15 70
Figure 22: Actos sales by geography and analyst consensus ($m), 2003–15 75
Figure 23: ACTOplus met sales by geography and analyst consensus ($m), 2003–15 75
Figure 24: Lupron Depot sales by geography and analyst consensus ($m), 2003–15 78
Figure 25: Velcade sales by geography and analyst consensus ($m), 2003–15 81
Figure 26: Alogliptin sales by geography and analyst consensus ($m), 2003–15 86
Figure 27: Alogliptin/ACTOS combo sales by geography and analyst consensus ($m), 2003–15 86
Figure 28: Enbrel sales by geography and analyst consensus ($m), 2003–15 89
Figure 29: Amitiza sales by geography and analyst consensus ($m), 2003–15 92


[Inhaltsverzeichnis ausblenden]